- Home
- EVT vs IDYA Comparison
EVT vs IDYA Comparison
Compare EVT & IDYA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EVT
- IDYA
- Stock Information
- Founded
- EVT 2003
- IDYA 2015
- Country
- EVT United States
- IDYA United States
- Employees
- EVT N/A
- IDYA N/A
- Industry
- EVT Finance Companies
- IDYA Biotechnology: Pharmaceutical Preparations
- Sector
- EVT Finance
- IDYA Health Care
- Exchange
- EVT Nasdaq
- IDYA Nasdaq
- Market Cap
- EVT 1.8B
- IDYA 2.0B
- IPO Year
- EVT N/A
- IDYA 2019
- Fundamental
- Price
- EVT $23.95
- IDYA $21.85
- Analyst Decision
- EVT
- IDYA Strong Buy
- Analyst Count
- EVT 0
- IDYA 13
- Target Price
- EVT N/A
- IDYA $53.67
- AVG Volume (30 Days)
- EVT 121.5K
- IDYA 943.3K
- Earning Date
- EVT 01-01-0001
- IDYA 02-13-2025
- Dividend Yield
- EVT 7.72%
- IDYA N/A
- EPS Growth
- EVT N/A
- IDYA N/A
- EPS
- EVT N/A
- IDYA N/A
- Revenue
- EVT N/A
- IDYA $7,000,000.00
- Revenue This Year
- EVT N/A
- IDYA $111.81
- Revenue Next Year
- EVT N/A
- IDYA $240.55
- P/E Ratio
- EVT N/A
- IDYA N/A
- Revenue Growth
- EVT N/A
- IDYA N/A
- 52 Week Low
- EVT $18.70
- IDYA $19.96
- 52 Week High
- EVT $23.82
- IDYA $47.72
- Technical
- Relative Strength Index (RSI)
- EVT 35.60
- IDYA 43.52
- Support Level
- EVT $24.12
- IDYA $19.96
- Resistance Level
- EVT $24.46
- IDYA $21.65
- Average True Range (ATR)
- EVT 0.26
- IDYA 1.09
- MACD
- EVT -0.05
- IDYA -0.07
- Stochastic Oscillator
- EVT 2.83
- IDYA 33.57
About EVT Eaton Vance Tax Advantaged Dividend Income Fund of Beneficial Interest
EATON VANCE TAX ADVANTAGED DIVIDEND INCOME FUND is a diversified, closed-end management investment company. Its objective is to provide a high level of after-tax total return consisting mainly of tax-advantaged dividend income and capital appreciation. The fund pursues its objective by investing in dividend-paying common and preferred stocks. Its portfolio of investments consists of electric utilities, energy equipment and services, food products, health care providers and services, internet software and services, and other areas.
About IDYA IDEAYA Biosciences Inc.
IDEAYA Biosciences Inc is an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. It is engaged in applying capabilities across multiple classes of precision medicine, including direct targeting of oncogenic pathways and synthetic lethality. The company's product candidate IDE196 is a protein kinase C, or PKC, an inhibitor for genetically defined cancers having GNAQ or GNA11 gene mutations.